Abstract
The common mechanism of action of aspirin and the chemically unrelated non-steroidal anti-inflammatory drugs (NSAIDs) is the inhibition of prostaglandin (PG) production due to interference with the enzymatic activity of cyclooxygenase (COX). These agents have long been used as effective treatments for arthritis. The recognition that the inducible isoform COX-2 was associated with inflammation and arthritis led to the hypothesis that PGs produced by a COX-2-dependent pathway were responsible for the inflammation, pain, and tissue destruction. Since the constitutive COX-1 enzyme was identified as responsible for gastroprotection and inhibition of platelet function, the potential for compounds that were both effective and safer than NSAIDs led to rapid development of agents that specifically inhibit COX-2. These agents have now been tested and approved for use by the US Food and Drug Administration for patients with osteoarthritis and rheumatoid arthritis. They have been shown equally effective to comparitor NSAIDs. More importantly, there is a 3.5-fold reduction in the incidence of endoscopic gastroduodenal ulcerations and early data suggesting a similar reduction in clinically significant perforations, symptomatic ulcers, and bleeds. In patients with arthritis at risk for gastrointestinal complications of NSAIDs, specific inhibitors of COX-2 provide an effective and apparently safer form of anti-inflammatory agent.
Current Pharmaceutical Design
Title: Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Volume: 6 Issue: 17
Author(s): Leslie J. Crofford
Affiliation:
Abstract: The common mechanism of action of aspirin and the chemically unrelated non-steroidal anti-inflammatory drugs (NSAIDs) is the inhibition of prostaglandin (PG) production due to interference with the enzymatic activity of cyclooxygenase (COX). These agents have long been used as effective treatments for arthritis. The recognition that the inducible isoform COX-2 was associated with inflammation and arthritis led to the hypothesis that PGs produced by a COX-2-dependent pathway were responsible for the inflammation, pain, and tissue destruction. Since the constitutive COX-1 enzyme was identified as responsible for gastroprotection and inhibition of platelet function, the potential for compounds that were both effective and safer than NSAIDs led to rapid development of agents that specifically inhibit COX-2. These agents have now been tested and approved for use by the US Food and Drug Administration for patients with osteoarthritis and rheumatoid arthritis. They have been shown equally effective to comparitor NSAIDs. More importantly, there is a 3.5-fold reduction in the incidence of endoscopic gastroduodenal ulcerations and early data suggesting a similar reduction in clinically significant perforations, symptomatic ulcers, and bleeds. In patients with arthritis at risk for gastrointestinal complications of NSAIDs, specific inhibitors of COX-2 provide an effective and apparently safer form of anti-inflammatory agent.
Export Options
About this article
Cite this article as:
Crofford J. Leslie, Clinical Experience with Specific COX-2 Inhibitors in Arthritis, Current Pharmaceutical Design 2000; 6 (17) . https://dx.doi.org/10.2174/1381612003398753
DOI https://dx.doi.org/10.2174/1381612003398753 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Omega-3 Fatty Acids Supplementation in Psychiatric Disorders: A Systematic Review
Current Psychopharmacology Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Toll-Like Receptors: Sensor Molecules for Detecting Damage to the Nervous System
Current Protein & Peptide Science Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Ankylosing Spondylitis, HLA-B27, Klebsiella and “Popper Sequences”
Current Rheumatology Reviews Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Can We Delay the Accelerated Lung Aging in COPD? Anti-Aging Molecules and Interventions
Current Drug Targets A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency
Endocrine, Metabolic & Immune Disorders - Drug Targets Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry Further Vitamin D Analogs
Current Vascular Pharmacology Trafficking of HIV-1 RNA: Recent Progress Involving Host Cell RNABinding Proteins
Current Genomics Review of Pediatric Uveitis
Current Pediatric Reviews The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Genetic Susceptibility to Autoimmune Disorders: Clues from Gene Association and Gene Expression Studies
Current Molecular Medicine Defining Novel Targets for Intervention in Rheumatoid Arthritis: An Overview
Current Rheumatology Reviews Amphiphilic Oligomers: A New Kind of Macromolecular Carrier of Antimitotic Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Virally Encoded G Protein-Coupled Receptors: Targets for Potentially Innovative Anti-Viral Drug Development
Current Drug Targets Contribution of Reactive Oxygen Species to Cartilage Degradation in Rheumatic Diseases: Molecular Pathways, Diagnosis and Potential Therapeutic Strategies
Current Medicinal Chemistry A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology